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Abstract
Background
A critical challenge in the management of Glioblastoma Multiforme (GBM) tumors is the
accurate diagnosis and assessment of tumor progression in a noninvasive manner. We
have identified Membrane-type 1 matrix metalloproteinase (MT1-MMP) as an attractive bio-
marker for GBM imaging since this protein is actively involved in tumor growth and progres-
sion, correlates with tumor grade and is closely associated with poor prognosis in GBM
patients. Here, we report the development of an immunoPET tracer for effective detection of
MT1-MMP in GBMmodels.
Methods
An anti-human MT1-MMP monoclonal antibody (mAb), LEM2/15, was conjugated to p-iso-
thiocyanatobenzyl-desferrioxamine (DFO-NCS) for 89Zr labeling. Biodistribution and PET
imaging studies were performed in xenograft mice bearing human GBM cells (U251)
expressing MT1-MMP and non-expressing breast carcinoma cells (MCF-7) as negative
control. Two orthotopic brain GBMmodels, patient-derived neurospheres (TS543) and
U251 cells, with different degrees of blood-brain barrier (BBB) disruption were also used for
PET imaging experiments.
Results
89Zr labeling of DFO-LEM2/15 was achieved with high yield (>90%) and specific activity (78.5
MBq/mg). Biodistribution experiments indicated that 89Zr-DFO-LEM2/15 showed excellent
potential as a radiotracer for detection of MT1-MMP positive GBM tumors. PET imaging also
indicated a specific and prominent 89Zr-DFO-LEM2/15 uptake in MT1-MMP+U251 GBM
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tumors compared to MT1-MMP-MCF-7 breast tumors. Results obtained in orthotopic brain
GBMmodels revealed a high dependence of a disrupted BBB for tracer penetrance into
tumors. 89Zr-DFO-LEM2/15 showedmuch higher accumulation in TS543 tumors with a highly
disrupted BBB than in U251 orthotopic model in which the BBB permeability was only partially
increased. Histological analysis confirmed the specificity of the immunoconjugate in all GBM
models.
Conclusion
A new anti MT1-MMP-mAb tracer, 89Zr-DFO-LEM2/15, was synthesized efficiently. In vivo
validation showed high-specific-contrast imaging of MT1-MMP positive GBM tumors and
provided strong evidence for utility of MT1-MMP-targeted immunoPET as an alternate to
nonspecific imaging of GBM.
Introduction
Glioblastoma Multiforme (GBM) is the most common malignant tumor of the central nervous
system (CNS) in adults. It belongs to a larger class of tumors known as glioma which arise
from the astrocytic glial cells[1]. The World Health Organization has divided astrocytic-
derived tumors into four grades based on their ability to infiltrate the surrounding brain tissue.
Grade I glioma consists of benign pilocytic and other non-infiltrating tumors, while Grade II,
III, and IV comprise infiltrating gliomas with increased malignancy[2]. GBM is a Grade IV gli-
oma, corresponding with the most malignant form and has the worst prognosis. These tumors
are also the most treatment-resistant and are difficult to image because of their diffuse infiltra-
tive and proliferative features. Despite the recent advances in the understanding of their biol-
ogy and in multimodality diagnostic and therapeutic procedures, these tumors maintain a high
recurrence after treatment with very poor prognosis and increasing morbidity and mortality.
Clinical management is often compromised by an imprecise delineation of tumor bound-
aries, lack of assessment of the tumor sensitivity to a given therapy and late detection of recur-
rences. The currently employed imaging diagnostic tools, computed tomography (CT) and
magnetic resonance imaging (MRI) provide excellent anatomical information on the localiza-
tion of brain lesions, but are frequently not able to differentiate tumor tissue from other
concurrent processes such as inflammation, edema or bleeding that give rise to under or over
estimation of the actual extension of the tumor. In addition, the tumor response to treatment is
conventionally measured by size change with MRI; however, this method does not consider the
biological steps preceding the tumor reduction and prognostic evaluation cannot be obtained
until weeks after the treatment initiation. These drawbacks make necessary to seek other non-
invasive molecular imaging-based technologies that allow efficient and safe diagnosis providing
additional and complementary biological information of the tumor. Positron Emission Tomog-
raphy (PET) is widely used in oncology for staging, monitoring the efficacy of a given treatment
and follow-up of a tumor recurrence because it offers an in vivo quantitative and comprehensive
evaluation at the molecular level[3]. Conventional 18F-Fluorodeoxyglucose (18F-FDG) imaging
is of limited usefulness for imaging GBM due to high levels of glucose uptake by normal brain
resulting in a low signal-background ratio. Additionally, increase in FDG uptake is not a cancer-
specific process as it has also been observed in inflammatory lesions and may lead to false-posi-
tive results[4]. Consequently, several preclinical and clinical studies have investigated the use of
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alternative PET radiotracers, such as labeled amino acids and their analogs 11C-Methionine
(11C-MET), 18F-fluoroethyl-tyrosine (18F-FET) and 18F-fluoro-dihydroxyphenylalanine
(18F-FDOPA)[5–7]; nucleoside radiotracers such as 18F-Fluorothymidine (18F-FLT)[8,9] with
specificity for thymidine kinase-1 (TK-1) whose activity is elevated in the normal cellular S-
phase and neoplastic tissues[10] or hypoxic tracers as 18F-Fluoromisonidazole (18F-FMISO)
[11]. Despite of showing a better detection of neoplastic tissue and treatment monitoring than
glucose imaging, there is still a clinical need to analyze more specific molecular events and pro-
cesses that could have a major impact on the understanding of glioma biology, for grading and
prognosis and on selection and monitoring of therapies. A promising option to improve diag-
nostic imaging is the immunoPET, which combines the high sensitivity, and quantitative capa-
bilities of PET with the specificity and selectivity of monoclonal antibodies (mAb) against a
given tumor cell surface marker. This combination makes this technique comparable to conduct
a noninvasive, in vivo quantifiable, three-dimensional full-body immunohistochemistry allow-
ing the diagnosis and monitoring of patients over time in a non-invasive manner
Membrane type 1-Matrix Metalloproteinase (MT1-MMP, also known as MMP14) has
emerged as an attractive biomarker for tumor-targeted antibody development since this pro-
tein is crucial for the progression, invasion, migration and angiogenesis of tumors[12,13]; and
specifically, its expression correlates with tumor grade and it is associated with reduced survival
in gliomas[14,15] and other cancers[16]. In addition, a growing body of evidence reveals that
overexpression of MT1-MMP plays also a significant role in promoting gliomagenesis[17].
MT1-MMP is broadly expressed in a variety of tissues and cell types including endothelial cells
[18]. It belongs to a subset of zinc-dependent membrane-anchored MMPs able to degrade the
basement membrane and proteins of the extracellular matrix (ECM)[19], cell adhesion mole-
cules, cytokines, growth factors and receptors[20]. Many studies have highlighted its potential
also as a therapeutic target in glioblastoma and other cancers[21,22]. In fact, a small molecule
inhibitor, Marimastat, targeting MMP active site was tested in clinical trials with GBM patients
[23,24]. However, this inhibitor failed because of unspecific inhibition of other MMPs with
structurally conserved active sites leading to undesired side effects. Nonetheless, several highly-
specific inhibiting antibodies such as DX-2400[25], 9E8[26] or LEM-2/15[27,28] have recently
revived MT1-MMP as promising therapeutic target[29]. Besides, MT1-MMP would represent
a candidate biomarker that can be leveraged for diagnostic purposes using specific probes, pro-
viding additional valuable information. Several studies using specific antibodies or peptides
have demonstrated that molecules capable of tracing MT1-MMP might be used as imaging
agents in several cancer models[30–32].
In the present study, we report the successful noninvasive detection of GBM tumors by PET
imaging, using a radiolabeled MT1-MMP-specific mAb (LEM2/15) in mice xenografted with a
glioma cell line expressing MT1-MMP or with patient-derived orthotopically implanted gli-
oma tumor neurospheres. As a PET nuclide, we used 89Zr with a half-life (t1/2) of 78.4 h that
is compatible to pharmacokinetics of intact antibodies (typically 2–4 days). The anti-MT1-
MMP antibody was functionalized with an isothiocyanate-bearing derivate of desferrioxamine
(DFO-NCS) as the 89Zr chelator. Our results support the feasibility of using noninvasive anti-
body-mediated PET imaging based on MT1-MMPmarker to specifically visualize GBM
tumors for diagnostic purposes.
Materials and Methods
Cell lines
GBM cell lines and neurospheres were kindly provided in 2012 by the Holland and Mellinghoff
laboratories (MSKCC). SK-mel-103 cells were received from the Soengas laboratory (CNIO) in
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2013. U251, T98G, U87-MG, SF-268, SF-295, MCF-7 and SK-mel103 cell lines were grown at
37°C in Dulbecco's Modified Eagle's Medium (Sigma) containing 10% FBS (Sigma). TS516,
TS543, TS568, TS676 neurospheres are cultured in suspension in human NSC Basal Medium
with NSC proliferation supplement, 1 mg/ml heparin (Stem Cell Technologies), 10 ng/ml
recombinant human EGF (Invitrogen) and 20 ng/ml recombinant human basic FGF (Sigma).
Primary tumor spheres were collected, mechanically disaggregated to a single-cell suspension
and propagated by serial passaging.
Protein isolation and immunoblotting
Whole protein lysates were isolated from cells lysed in NP-40 lysis buffer (0.5% NP-40, 50 mM
Tris-HCl [pH 7.5], 50 mM NaCl, 1x phosphatase inhibitor cocktail set II (Calbiochem) and
protease inhibitor cocktail set III EDTA-free (Calbiochem), and protein quantified by BCA
assay (Pierce). Protein lysates were (100 μg per lane) separated by SDS-PAGE and transferred
to nitrocellulose membranes (Amersham) for immunoblotting. Membranes were probed with
antibodies against MT1-MMP (LEM2/15) and detected using HRP-conjugated anti-mouse
antibodies (Dako) using chemiluminescence detection (ECL, Amersham).
Flow cytometry
Cell lines were detached from dishes using Cell Dissociation Buffer, enzyme-free, PBS (Life
Technologies). After counting, single cell suspensions in FACS buffer (1% IgG Free BSA in
PBS (Sigma)) were incubated with 1μl of Fc Block (BD) for every million cells for at least 15
min at 4°C. Cells were then stained with the LEM 2/15 purified antibodies at the indicated con-
centrations for 15 min at 4°C, washed twice with FACS buffer. Cells were then incubated with
appropriate fluorophore-conjugated secondary antibody (Molecular Probes, Invitrogen) at a
dilution 1:500 for 15 min at 4°C, washed with FACS buffer, and resuspended in FACS buffer
containing DAPI (5mg/ml diluted 1:5,000) for live/dead cell exclusion. Antibodies used for
flow cytometry include LEM 2/15 obtained from ascytes, purified from cell culture, DFO con-
jugated and 89Zr labeled and decayed. For analysis, samples were run on a BD LSR II (Becton
Dickinson), and all subsequent compensation and gating performed with FlowJo analysis soft-
ware (TreeStar).
Radiolabeling of antibody
Hybridoma cells of LEM2/15 were cultured as described previously[27], and the mAb was
purified from the hybridoma supernatant according to standard methods using Protein A-
based chromatography. The bifunctional chelator DFO-NCS (Macrocyclics, Dallas, TX) was
conjugated to LEM 2/15 and subsequent 89Zr radiolabeling was performed by adaptation of
published protocols[33,34]. 89Zr (T1/2 = 78.4 h, β
+ = 22.6%; ~2.7 GBq/ml supplied in 1 M oxalic
acid) was obtained from BV Cyclotron VU (Amsterdam, The Netherlands).
For conjugation, 2 mg of LEM 2/15 in 1 ml solution at pH 9.0, adjusted with 0.1 M Na2CO3
(max. 100 μl), were mixed with DFO-NCS (dissolved in DMSO at a concentration 3.5 mM) at
a molar ratio of 1:5. The reaction was incubated for 40 min at 37°C. Non-conjugated chelator
was removed by G25-Sephadex size-exclusion chromatography using a PD10 column (GE
Healthcare Life Sciences) and 5 mg/ml gentisic acid in 0.25 M sodium acetate trihydrate (pH
5.4–5.6) as eluent.
For radiolabeling, the required volume of 89Zr-oxalic acid solution corresponding to 37–74
MBq was adjusted to a total volume of 200 μl using 1 M oxalic acid, 90 μl of 2 M Na2CO3 were
added and incubated for 3 min at room temperature. One ml of 0.5 M HEPES and 710 μl of
DFO-LEM 2/15 (1 mg/ml) were subsequently added and incubated at room temperature for
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90 min on a rotating shaker. pH was checked to be at 7.0–7.5. Finally, the reaction mixture was
loaded onto a previously equilibrated PD-10 column and eluted with phosphate-buffered saline
(PBS) into fractions of 500 μL. After purification, the collected fractions were measured in a
dose calibrator (IBC, Veenstra Instruments). Quality control was performed by instant thin-
layer chromatography (ITLC) on ITLC strips (model 150–771, Biodex) using 0.02 M citrate
buffer (pH 5.0):acetonitrile (9:1) as eluent.
The stability of 89Zr-DFO-LEM 2/15 was investigated by incubation in human serum for 7
days at 4°C and 37°C. The radiochemical purity was determined by ITLC as discussed above.
The DFO-NCS to LEM 2/15 molar ratio was determined before removing unconjugated
chelate. Thus, a small aliquot of the reaction mixture was reacted with a tracer amount of 89Zr-
oxalic acid for 90 min at room temperature. The mixture was put on a PD-10 column and
eluted with PBS. The percentage of radioactivity present at the antibody fraction was then
determined. The number of chelating molecules incorporated per antibody was calculated
from the labeling efficiency and the molar ratio of added chelating agent to antibody.
The same procedure described for 89Zr-DFO-LEM 2/15 was followed to produce the 89Zr-
labeled non-specific mouse IgG1 (BioXCell, USA) used as isotype control antibody (89Zr-
DFO-IgG1).
Subcutaneous and orthotopic tumor mouse models
For subcutaneous heterotopic xenografts 750,000 U251 or 1,000,000 MCF-7 cells were resus-
pended in 200μl of a 1:1 mix of DMEM (Sigma) with Matrigel (BD Biosciences). Next, the
Matrigel:DMEM-cells mixture was injected subcutaneously into the flanks of 6 weeks athymic
nude mice (Nude-Foxn1nu, Harlan Laboratories). Tumors were allowed to develop until pal-
pable prior immunoPET analysis and were measured 3 times per week by caliper. Mice were
sacrificed when the tumor mass reached a maximum size of 1500 mm3 or tumor ulceration
was observed or mice were symptomatic from their tumors which included signs of lethargy,
poor grooming, weight loss and hunching.
For orthotopic xenografts, U251 cells and primary TS543 neurospheres were transduced
with a TK-GFP-Luciferase reporter plasmid (TGL) to monitor tumor growth by biolumines-
cence measurements and were described previously[35]. TS543 cells were previously used in
intracranial PET imaging studies[36]. To develop intracranial tumors athymic nude mice
(Harlan) were fully anesthetized with 10mg/ml ketamine and 1mg/ml xylazine and were sub-
cutaneously injected with 50μl of the local anesthetic 0.25% bupivacaine at the surgical site.
Mice were intracranially injected with 1.5μl containing 2,5 x 105 U251-TGL cells or 5 x 104
TS543-TGL (resuspended in PBS) at 6 weeks of age using a fixed stereotactic apparatus (Stoelt-
ing). Injections were made to the right frontal cortex, approximately 1 mm caudal and 1.5 mm
lateral from bregma, and at a depth of 2 mm using a Hamilton syringe (Hamilton) as described
previously[37]. Tumor growth was monitored by luminescence. Mice were injected with
D-Luciferin (150 mg/kg). 15 minutes after injection, images were acquired for 5 seconds using
an IVIS200 machine (Perkin Elmer). Bioluminescence analysis was performed using Living
Image software, version 2.50. When tumors were in a positive growth phase determined by bio-
luminescence imaging (BLI) output, immunoPETs were performed. Mice were monitored by
BLI every 3 days and sacrificed at the time points described or when they became symptomatic
from their tumors, which included signs of lethargy, poor grooming, weight loss, hunching,
macrocephaly or seizures. All animal experiments were performed according to protocols
approved by the CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA)
and they were performed in accordance with the guidelines stated in the International Guiding
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Principles for Biomedical Research Involving Animals, developed by the Council for Interna-
tional Organizations of Medical Sciences (CIOMS).
Pharmacokinetic and biodistribution studies
Four groups of 4 female athymic mice each bearing U251 cells in flanks were injected i.v. (tail
vein) with 1.5 MBq (20 μg) of 89Zr-DFO-LEM 2/15. Mice were euthanized at 1, 2, 4 and 7 days
after injection by cervical dislocation under anesthesia with isofluorane in O2 and blood was
immediately collected by cardiac puncture. For biodistribution studies organ tissues and
tumors were excised, wet-weighed and counted for radioactivity with a gamma-counter (2470
Wizard2, PerkinElmer), along with a standard sample of the injected dose. Tissue activity was
expressed as percentage injected dose per gram of tissue (%ID/g). Subsequently, tumors were
formalin-fixed and stored at 4°C for immunohistochemical assays. For pharmacokinetic stud-
ies, blood samples were collected in heparinized tubes and centrifuged at 3000 rpm for 10 min
to obtain plasma. Plasma concentrations of radioactivity were calculated as the percent injected
dose per mL (%ID/mL) and were plotted versus the time post-injection. Pharmacokinetic
parameters were estimated by noncompartmental analysis[38] using the computer program
WinNonlin Professional, version 5.2 (Pharsight Corporation, Mountain View, CA, USA).
microPET/CT imaging
Eleven mice bearing breast cancer cells (non-expressing MT1-MMP) in one flank and GBM
cells (expressing MT1-MMP) in the contralateral side were injected i.v. (tail vein) with 1.5
MBq (20 μg) of 89Zr-DFO-LEM 2/15 and scanned with a small-animal Argus PET-CT scanner
(SEDECAL, Madrid, Spain). The PET studies (energy window 250–700 KeV and 30 min static
acquisition) and CT (voltage 45 kV, current 150 μA, 8 shots, 360 projections and standard res-
olution) were performed at various time points post-injection (1, 2, 4 and 7 days) in mice anes-
thetized by inhalation of 2–2.5% Isofluorane. The PET images were reconstructed using a
2D-OSEM (Ordered Subset Expectation Maximization) algorithm (16 subsets and two itera-
tions), with random and scatter correction. Manually drawn regions of interest (ROIs) were
used to determine the mean radiotracer accumulation in units of %ID/g tissue (decay corrected
to the time of injection) in both tumors, brain (used as background tissue), and heart (used
as blood pool). Images were analyzed using the image analysis software ITK-SNAP (www.
itksnap.org). With the aim to obtain a more accurate quantification of the radiotracer in
tumors, PET images were corrected for partial volume effect using tumor volume segmented
from coregistered CT images. Recovery coefficients (RC, ratio between measured and true
activity and used to correct the partial volume effect), were calculated using the phantom
described in the NEMA NU 4–2008 protocol[39].
For the orthotopic models (n = 3–5) PET/CT scans were performed as described above.
Immunohistochemistry
MT1-MMP expression was analysed on a human glioma tissue microarray (TMA) from the
CNIO Biobank, comprised by a total of 40 different formalin-fixed paraffin-embedded samples
in duplicate, 20 of high grade glioma (HGG, WHO grade IV, GBM) and 20 of low grade glioma
(LGG, 15 of WHO grade II and 5 of WHO grade I). Immunohistochemical staining was per-
formed using anti-MT1-MMP LEM 2/15 antibody at 1:400 dilution after antigen retrieval with
low pH buffer in Autostainer platform (Dako) and counterstained with hematoxylin. Slides
were digitalized using the Mirax Scan (Carl Zeiss AG, Oberkochen, Germany) and pictures
were taken with the Pannoramic Viewer software (3D Histech Ltd., Ramsey, NJ, USA).
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On the other hand, tumor-bearing mice were sacrificed after the last 48 h PET imaging and
tumors or brains were excised, fixed in 10% buffered formalin (Sigma) and embedded in paraf-
fin. For histopathological analysis, tissues were serially sectioned (3 μm) and stained with
hematoxylin and eosin (H&E). For analysis of MT1-MMP expression, immunohistochemical
staining was performed as described above.
For double staining immunohistochemistry, slides were incubated sequentially with the
appropriate first and second primary antibodies as detailed: anti-MT1-MMP LEM 2/15 anti-
body (1/400) followed by rabbit polyclonal anti-CD31 (1:50, Abcam ab28364) or anti-MT1-
MMP LEM 2/15 antibody (1/400) followed by pre-diluted rabbit monoclonal anti-Ki67 (clone
MIB1, Dako). After the primary antibody, slides were incubated with the corresponding visual-
ization systems as needed (OmniRabbit, Ventana; Roche or Goat anti Rabbit; Dako) conju-
gated with horseradish peroxidase and UltraMap anti-Rb Alk Phos (Ventana; Roche)
conjugated with alkaline phosphatase. Immunohistochemical reaction was developed using
using 3,30-diaminobenzidine tetrahydrochloride (DAB) as chromogen (Chromomap DAB;
Ventana, Roche) or naphthol-AS-phosphate and fast red (Chromomap Red; Ventana, Roche).
Finally, nuclei were counterstained with Carazzi’s hematoxylin. Digital slides were acquired as
described above.
Evaluation of the BBB disruption by Evans Blue staining
The alteration of the BBB was determined by following procedures previously described by
Manaenko et al. [40]. 6–8 weeks old athymic/nude mice were intracraneally injected with
U251-TGL and TS543-TGL cells using a fixed stereotactic apparatus (Stoelting) and monitored
for brain tumor development as described above for PET imaging. Littermates were mock
injected with 1.5μl of PBS as controls and sacrificed at the same time. Non injected athymic/
nude littermates were included as intact brain controls.
To evaluate the BBB status, mice were injected IP with 800 ul of 2% Evan's blue dye (Sigma).
One hour after injection, mice were anesthetized and perfused with acidified fixative (1% PFA
in 0.05 mM citrate buffer, pH 3.5). Thirty mg of brain tissue were incubated in 500 μl formam-
ide (Sigma) to extract Evan's blue at 60°C overnight. Absorbance was measured at 610 nm and
740 nm on a plate reader (Sinergy 4, BioTek Instruments, USA).
Ex vivo Autoradiography
After PET/CT scans at 48 hours after injection, mice were euthanized, and tumors or whole
brains bearing orthotopic tumors were removed and frozen in the OCT compound (Tissue-
Tek, USA). The frozen tissues were sectioned into 30-μm thick slices by a cryostat (CM 1850,
Leica). Autoradiography (ARG) was acquired by exposing the frozen sections to a phosphor
screen, using a STORM 820 Phosphor Imager (GE Healthcare). For staining techniques after
autoradiography, frozen samples were serially cut at 10 μm and mounted on glass slides,
thawed and allowed to dry for 30 minutes. Slides were then fixed in 10% neutral buffered for-
malin for 10 minutes. Consecutive sections were stained with hematoxylin and eosin (H&E)
and for immunohistochemistry analysis with LEM2/15, as described above.
REMBRANDT Dataset
Glioma expression data of the REMBRANDT dataset [41] were analyzed through the GlioVis
portal (http://gliovis.bioinfo.cnio.es). Data can be accessed at the GlioVis portal or at The
Georgetown Database of Cancer Plus (https://gdoc.georgetown.edu/gdoc/).
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Statistical Analysis
Tukey's honest significant differences (HSD) in conjunction with ANOVA were performed for
multiple comparison analysis using the R statistical software. Data in bar graphs are presented
as the mean±SD. Statistical analysis was performed using the Mann-Whitney test for nonpara-
metric data and the unpaired t test for parametric data. The Grubbs test was applied to detect
eventual outliers in data sets with the online “Outlier Calculator” tool (http://www.graphpad.
com/quickcalcs/Grubbs1.cfm). A P value of 0.05 or less was considered significant.
Results
Validation of MT1-MMP as suitable biomarker of GBM
To determine whether MT1-MMP could be considered as an appropriate biomarker for glio-
mas, we studied its expression in a panel of 40 human glioma samples (WHO grade I, II and
IV) by tissue microarray immunohistochemical analysis, using the anti-MT1-MMP LEM 2/15
antibody. A higher level of expression of MT1-MMP in GBM (HGG) was found as compared
to low-grade gliomas (LGG) (Fig 1A) and it could be detected mainly in tumors but also in
some endothelial cells. Moreover, analysis of a panel of different glioma cell lines and tumor
neurospheres (TS) by immunoblot (Fig 1B) and FACS (Fig 1C) showed high MT1-MMP
expression. Importantly, the ability of LEM-2/15 mAb to recognize intact MT1-MMP by FACS
highlights its potential use for in vivo applications like immunoPET. Further validation with
glioma patient public datasets was performed confirming that an increase of MT1-MMP
expression at the mRNA level in GBM is observed compared to LGGs as oligodendroglioma
and astrocytoma (grade II and III) (S1A and S1B Fig) and that high levels of MT1-MMP are
associated with worse prognosis and a decreased survival in GBM patients (S1C Fig).
Characterization and stability of 89Zr-DFO-LEM2/15
Selected conjugation conditions comprised the addition of a five-fold molar excess of
DFO-NCS to the LEM2/15 solution, a reaction pH of 9.0, and incubation for 40 min at 37°C.
These conditions resulted in a chelate:mAb substitution ratio of about 2–3:1. The radiochemi-
cal yield, purity, and specific activity of the 89Zr-DFO-LEM 2/15 used in this study were>90%,
>98% and 78.5 ± 7.2 MBq/mg (n = 4) respectively, assuming virtually complete recovery of the
DFO-mAb conjugates after size exclusion chromatography. Incubation of 89Zr-DFO-LEM 2/
15 in human serum for 7 days, at 4°C or 37°C, revealed a stability of 99.2 ± 0.5% (n = 3) and
99.1± 0.3% (n = 3), respectively.
Biodistribution and pharmacokinetics of 89Zr-LEM 2/15
Biodistribution experiments using 89Zr-LEM 2/15 (Fig 2) were conducted in nude mice bearing
MT1-MMP expressing U251 and revealed a normal antibody organ distribution. In GBM
tumors, the higher uptake is observed 24h post-injection (22.63±3.67%ID/g) and then it
decreased in a time-dependent manner. Data showed high liver retention (27.47±3.3%ID/g))
compared to the spleen, kidneys and lungs, spanning a range between 5–15%ID/g which is rep-
resentative of the hepatic clearance of full-length IgGs. The activity of the rest of organs and tis-
sues was low (often below 5%ID/g) and decreased gradually with time except for bone which
shown an increasing uptake along time.
Pharmacokinetic studies determined that the terminal phase half-life and the mean resi-
dence times were 3.2 and 4.5 days, respectively, and the volume of distribution at steady state
was 2.15 mL (84 mL/kg). The systemic clearance was 0.47 mL/d (18.4 mL/d/kg), value in agree-
ment with those obtained for therapeutic monoclonal antibodies in mice[42].
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89Zr-DFO-LEM 2/15 PET imaging of subcutaneous glioma xenografts
89Zr-DFO-LEM 2/15 small-animal PET was conducted on mice harboring xenograft tumors at
opposite flanks with MT1-MMP+ GBM U251 cells and MT1-MMP- breast MCF7 cells. Assess-
ment of MT1-MMP expression in U251 and MCF7 by FACS and immunoblotting confirmed
high and null expression of U251 and MCF7, respectively (data not shown). Levels of radioac-
tivity in tumors, tumor-to-blood and tumor-to-background ratios were calculated. In tumors,
radioactivity decreased in a time-dependent manner, with the uptake being 18.3±2.6 (n = 11),
17.7±2.6 (n = 8), 14.3±2.0 (n = 6) and 10±1.4 (n = 4) %ID/g at 1, 2, 4 and 7 days p.i., respec-
tively in MT1-MMP+ U251 tumors, and 10.8±2.5 (n = 11), 11.4±2.3 (n = 8), 9.4±2.4 (n = 6)
and 6.8±1.7 (n = 4) %ID/g at 1, 2, 4 and 7 days p.i., respectively in MT1-MMP- MCF-7 tumors
(Fig 3A and 3B top panel and S1 Video). The uptake in MT1-MMP+ tumors was significantly
higher than in MT1-MMP- tumors at all times. Tumor/blood ratios in GBM/MT1-MMP+
tumors were 0.88±0.08, 1.07±0.19, 1.29±0.12 and 1.31±0.29 at 1, 2, 4 and 7 days post-injection,
Fig 1. MT1-MMP protein expression analysis. A) Immunohistochemistry with the LEM2/15 anti MT1-MMP
antibody in a TMA (n = 40) of Low-grade GBMs (LGG) and High-grade GBMs (HGG) patient tissues
(representative images). Right panel: MT1-MMP staining intensity score (0–3). B) Immunoblotting andC)
FACS analyses of the indicated cell lines using the LEM2/15 anti MT1-MMP antibody.
doi:10.1371/journal.pone.0158634.g001
Fig 2. Biodistribution of 89Zr-DFO-LEM2/15 in mice bearing MT1-MMP+ GBM cells (U251).
doi:10.1371/journal.pone.0158634.g002
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Fig 3. PET/CT imaging with radiolabeled 89Zr-DFO-LEM 2/15 in mice bearing MT1-MMP+ GBM cells
(U251) and MT1-MMP- breast cancer cells (MCF-7). A)Representative coronal whole-body PET and CT
sections at 1, 2 and 7 days p.i.;B) Levels of radioactivity in tumors, tumor to blood and tumor to background
ratios derived from PET imaging after 89Zr-DFO-LEM 2/15 administration to mice bearing MT1-MMP+ and
MT1-MMP- tumors (mean±SD, n = 11−4/time);C) Immunohistochemistry of tumor tissue from xenografted
mice used for PET imaging. MT1-MMP was detected using LEM2/15 antibody. Scale bars: 500 μm D)
Representative images of double immunostaining for MT1-MMP (pink) and CD31 vascular marker (brown)
(left panel) and for MT1-MMP (pink) and Ki67 proliferation marker (brown)(right panel) in U251 tumor implants
from xenografted mice used for PET imaging. Scale bars: 50 μm. Significant differences: p<0.05 (*), p<0.001
(**) and p<0.0001 (***), ns, not significant.
doi:10.1371/journal.pone.0158634.g003
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respectively (Fig 3B middle panel). However, tumor/blood ratios in breast MT1-MMP- cells
were significantly lower (0.51±0.15, 0.67±0.23, 0.81±0.24 and 0.80±0.11 at 1, 2, 4 and 7 days
post-injection, respectively) than those for GBM/MT1-MMP+ tumors. Tumor/background
ratios in GBM/MT1-MMP+ tumors exhibited high values after 1 day (6.32±0.62, 5.77±0.77,
5.68±0.61 and 3.80±0.74 at 1, 2, 4 and 7 days p.i., respectively) in contrast to significantly lower
values obtained with breast MT1-MMP- tumors (3.74±0.92, 4.02±0.75, 3.73±0.95 and 2.60
±0.86 at 1, 2, 4 and 7 days p.i., respectively) (Fig 3B bottom panel). In addition, immunohisto-
chemical staining of tumors excised 48h after PET scan by using the LEM2/15 antibody con-
firmed high expression of MT1-MMP in the U251 xenograft (Fig 3C, left panel) and its
absence in the MCF7 tumor (Fig 3C, right panel). To obtain more detailed information with
regard to the localization of MT1-MMP expression within the tumor, double staining immu-
nohistochemistry analyses with LEM2/15 antibody and tumor (Ki67) or vascular (CD31)
markers were performed (Fig 3D). We determined that tumor cells (Ki67+) immunostained
strongly positive for MT1-MMP while most endothelial cells (CD31+) did not stain at all. This
would suggest that LEM2/15 does not recognize properly mouse MT1-MMP, therefore we
could exclude that the PET signal come from the endothelial cells. Digital autoradiography and
histologic staining revealed a homogeneous distribution of 89Zr-DFO-LEM 2/15 in the U251
tumors corresponding to the MT1-MMP-expressing regions (S2A Fig).
89Zr-DFO-LEM 2/15 PET imaging of intracranial xenograft tumors
To determine the applicability of PET imaging to GBM tumor in a more clinically relevant
mouse orthotopic model, PET/CT imaging with 89Zr-DFO-LEM2/15 and a control 89Zr-
DFO-IgG1 was performed 10 days after intracranial injections of patient-derived neurospheres
(TS543). Presence of tumors was confirmed by bioluminiscence. The brain PET image (Fig 4A
and S2 Video) shows that 89Zr-DFO-LEM2/15 was specifically accumulated in tumor, enabling
its accurate localization and delineation. Posterior quantitative analysis of tumor/blood ratios
of 89Zr-DFO-LEM2/15 compared with control 89Zr-DFO-IgG1 distribution (1.17±0.23 and
1.50±0.14 versus 0.71±0.10 and 0.82±0.01 at 2 and 4 days p.i., respectively) revealed significant
differences over time (Fig 4B and S3A Fig), indicating an MT1-MMP-mediated specific tumor
uptake in this model. Sections of mouse brains bearing the GBM xenografts immunostained
for MT1-MMP confirmed the expression of this protein in the tumor tissue but not in the sur-
rounding brain tissue or in vascular endothelial cells, where most of the tumor vessels were
negative for LEM2/15 staining (Fig 4C).
Interestingly, the 89Zr-DFO-LEM2/15 antibody only caused a very weak signal in an ortho-
topic U251 tumor model and did not show a significant difference between tumor/blood ratios
of the specific labeled antibody and control 89Zr-DFO-IgG1 (0.23±0.04 and 0.30±0.03 versus
0.17± 0.05 and 0.21± 0.10, at 2 and 4 days p.i., respectively) (S3A Fig), despite the considerably
higher expression of MT1-MMP on U251 cells as compared with TS543 neurospheres (Fig
1C). To test whether the differences in the 89Zr-DFO-LEM2/15 uptake, between the U251 and
TS543 orthotopic models, were associated to the integrity of the blood-brain barrier (BBB) we
performed an Evans blue (EB) staining. U251 tumors showed significantly lower EB staining
than TS543 tumors (9.14±3.14 versus 39.35±26.83 μg of EB/g tissue, respectively; intact or
mock surgery brain: 2.12±0.77 or 2.03±0.51μg of EB/g tissue, respectively) (S3B Fig), indicating
only partially increased BBB-permeability in the U251 model and a highly disrupted BBB in
the TS543 model.
In conclusion, small animal PET/CT using 89Zr-DFO-LEM2/15 mAb enabled the specific
and efficient detection of aggressive TS543 neurosphere-derived tumors in which the BBB is
disrupted.
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Discussion
GBM remains one of the most deadly form of human cancer despite tremendous advances in
surgical approaches, radiotherapy and chemotherapy over the last decades, with an average
survival of 14–16 months using the current standard of care based on administration of
radiotherapy and concomitant and adjuvant temozolomide [43][44]. Therefore, significant
improvements in understanding of molecular pathogenesis, as well as in diagnosis and novel
therapeutic strategies should be made to increase patient survival rates [45]. In particular,
accurate diagnosis has a key role in clinical management of GBM patients. Treatment follow-
up and clinical decision-making are currently based on the accuracy of non-invasive imaging
techniques such as MRI or PET targeting aberrant metabolic processes. MRI has limitations
in identifying tumor grade, invasive growth into neighboring tissue, treatment-induced
changes and recurrences because pseudoprogression and tumor progression cannot be prop-
erly distinguished [46]. PET imaging with 18F-FDG and especially other PET tracers such as
11C-MET, 11C-TYR, 18F-FET or 18F-DOPA have shown a great potential for cerebral GBM
diagnosis, however their sensitivity and specificity for detecting tumor growth or shrinkage
remains to be fully validated [47]. These drawbacks make necessary to seek urgently other
noninvasive biologic-based imaging with molecularly targeted agents such as immunoPET
Fig 4. PET/CT imaging with radiolabeled 89Zr-DFO-LEM2/15 in mice bearing orthotopic xenografts
containing patient-derived neurospheres. A) Representative fused PET/CT images of coronal and sagittal
planes at 2 and 4 days p.i. containing TS543 brain tumors with 89Zr-DFO-LEM2/15 (left panels) and 89Zr-
DFO-IgG1 as isotype control (right panels)B) Tumor-to-blood ratios for 89Zr-DFO-LEM2/15 (black bars) and
89Zr-DFO-IgG1 (grey bars) in nude mice bearing orthotopic TS453 xenografts at 2 and 4 days p.i. derived
from PET imaging. Values are presented as mean±SD (n = 3–5). C)Representative brain images of double
immunostaining for MT1-MMP (pink) and CD31 vascular marker (brown) (left panel) and for MT1-MMP (pink)
and Ki67 proliferation marker (brown) (right panel) from orthotopic TS453 xenografts used for PET imaging.
Higher-magnification are shown in the bottom panels. Scale bars: 20 μm. Significant differences: p<0.05 (*)
and p<0.0001 (***).
doi:10.1371/journal.pone.0158634.g004
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[48] that might improve the specificity of tumor diagnosis compared with the more anatomi-
cal based techniques.
Herein, we provide proof of concept that MT1-MMP expression can be quantitatively
assessed by an immunoPET using a specific monoclonal antibody (LEM 2/15), readily labeled
with 89Zr and used for in vivo tumor imaging. Furthermore, we evaluated the in vitro and in
vivo properties of this labeled antibody to develop a new PET probe for glioma detection, show-
ing that 89Zr-DFO-LEM2/15-mediated PET yields high resolution detailed images with high
tumor-to-background contrast in flank and orthotopic xenograft models of GBM. Therefore,
this study was performed to establish and validate MT1-MMP as a candidate for GBM diagno-
sis by means of noninvasive PET imaging.
We chose the function-blocking antibody LEM2/15 because it shows very high specificity
for MT1-MMP. It was generated against the V-B loop of MT1-MMP (residues 218–233) [27]
which is located outside the conserved catalytic cleft and therefore its epitope displays low
sequence homology among the MMP family. Recently, the crystal structure of Fab LEM2/15
complexed with the catalytic domain of MT1-MMP has shed light on the molecular mecha-
nism of the allosteric inhibition of this enzyme by the antibody [28]. This work pointed to the
potential utility of LEM2/15 as lead for the development of novel MMP-targeted therapeutics
[29]. In this context, our goal would also be the integration of LEM2/15-based PET into the
process of the drug development in preclinical studies and eventually for clinical translation to
monitor noninvasively target expression.
First, we tested whether MT1-MMP was indeed a suitable target for a PET biomarker of
GBM by studying extensively MT1-MMP expression at different levels. Utilizing bioinformat-
ics analysis of the REMBRANDT dataset, we confirmed a significant correlation between
increased MT1-MMP expression with advanced tumor grades, malignancy and shorter overall
survival for GBM patients, in concordance with previously reported results[15,17,49]. Further
validation was carried out at protein level, detecting MT1-MMP in a panel of glioma cells by
immunoblotting and FACS; and in a TMA immunohistochemistry staining with glioma sam-
ples of various grades, in which we documented a marked increase in expression of MT1-
MMP in GBM compared to low-grade gliomas. Altogether, our data suggested the feasibility of
MT1-MMP to become a suitable molecular target for GBM diagnosis. MT1-MMP overexpres-
sion would indicate tumor progression towards more aggressive phenotypes associated with a
worse prognosis, and also predict that the LEM2/15 antibody would have potential utility as
MT1-MMP-targeted PET probe for imaging of GBM.
Previous studies have explored the use of MT1-MMP as imaging biomarker in SPECT
[31,32,50], optical imaging[30] and PET/optical imaging using cleavable PEGylated MT1-
MMP substrate peptide probes conjugated with 18F-labeled BODIPY (boron dipyrromethene)
scaffold which allows an effective integration of fluorescence-based imaging with PET studies
to monitor MT1-MMP proteolytic activity [51]. However, to the best of our knowledge, this is
the first time that a MT1-MMP-based immunoPET is described for GBM detection and it is
expected to have greater performance than other MT1-MMP-based imaging systems devel-
oped up to now: immunoPET combines the antibody characteristics of high specificity, affinity
and great structural flexibility to generate a variety of fragments with half-lives matching opti-
mally the period of semi-desintegration of isotopes, with PET as imaging technique which pro-
vides higher spatial resolution and sensitivity than SPECT from a clinical perspective.
Concerning radiolabeling, experiments on different Zr coordination methods have reported
that 89Zr-DFO mAbs provides higher in vivo stability with respect to demetalation and rela-
tively low levels of radiotracer accumulation in background tissue, especially in bones[52] and
hence DFO is currently the best chelator for 89Zr[53]. The results reported here are consistent
with previous investigations and confirmed that 89Zr is a suitable radionuclide for labeling
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intact antibodies[33,54,55]. Biodistribution studies with the U251 murine model revealed spe-
cific MT1-MMP driven uptake of 89Zr-DFO LEM2/15 in GBM tumors (about 30%ID/g at
24h), declining in a time-dependent manner up to 15% ID/g at 7 days p.i. Most likely this
increased clearance of radioactivity at tumor site represents metabolism instead of loss of 89Zr,
due to lack of complex stability since 89Zr-DFO-LEM2/15 was very stable in serum, with no
significant dissociation of the complexes after 7 days. In non-target tissues, organs of the reticu-
loendothelial system showed relatively high uptake, especially liver, which is attributable to the
biological elimination of the tracer, given that antibodies are usually cleared through their
interaction with the Fc receptors expressed on cells of this system[56], and is a pattern fre-
quently observed with radiolabeled antibodies[57–59]. Also, an increasing accumulation of
activity in the bones is observed along time, just the same as in previous studies using DFO as a
chelator [60], since Zr ion shows a high affinity for bones[52].
Regardless of the antibody/antigen system, no in vivo investigation of an 89Zr-DFO-labeled
imaging probe is complete without a demonstration of selectivity. This can be achieved using a
cell line that does not express the antigen in question (i.e., MT1-MMP), such as MCF-7 cell
line used in the present study. To confirm that the accumulation of 89Zr-DFO-LEM2/15 was
attributable to specific rather than non-specific bindings, we implanted MT1-MMP-expressing
and non-expressing tumor cells within the same animal in the microPET/CT experiments.
Tumor/blood ratios of 89Zr-DFO LEM2/15 in GBMMT1-MMP+ tumors were significantly
higher than those in breast MT1-MMP- tumors, indicating the specificity of 89Zr-DFO-LEM2/
15 toward MT1-MMP. The unspecific accumulation of the antibody in breast tumors could be
due to the enhanced permeability and retention (EPR) effect, which is characterized by a leaky
nature of tumor vasculature and reduced lymphatic drainage [61], rather than an involvement
of the vasculature since LEM2/15 showed no reactivity with most of the mouse tumor blood
vessels by IHC. In fact, it has been previously described that LEM2/15 antibody reacted poorly
with MT1-MMP from murine origin [62].
Compared to some limitations of the subcutaneous model, orthotopic tumor models more
closely mimic the natural biologic behavior and characteristics of human tumors because they
grow in its native microenvironment and reliably replicate certain important characteristics.
For the generation of orthotopic GBM xenografts we employed neurospheres in addition to
established glioma cell lines such as U251 because these grafted masses structurally resemble
more to the tumor of origin. Intact antibodies are too large to cross readily the BBB[63] and
indeed we observed that a disrupted BBB is needed for the LEM2/15 antibody to penetrate into
the brain tumors. Accordingly, 89Zr-DFO LEM2/15 was able to detect orthotopically growing
GBM implants from TS543 but not from U251, which correlates with the integrity of the BBB,
as analyzed by Evans blue staining. More brain tumor models with different BBB leakage will
be utilized in the future to test the tracer activity. However, this high dependence on the BBB
integrity for targeting is a major limit for the use of intact LEM2/15 in clinical developments.
To overcome such a limitation, our current work is aimed at extending this initial findings
using engineered and miniaturized derivatives of the LEM2/15 antibody. The minituarized
antibodies can enhance BBB penetration and therefore result in an improved tumor-targeted
imaging[64]. Moreover labelling with PET isotopes characterized by short or intermediate
half-lives such as 68Ga[65] would optimize the pharmacokinetics and facilitate wide access to
this technology since 68Ga can potentially be generator-produced on site (rather than cyclotron
produced). Besides, future studies with different tumor grades are needed to confirm the
correlation between the MT1-MMP-targeted PET and the different tumor grades. Also, the
demonstration of the feasibility of MT1-MMP as biomarker for tumor progression, able to dis-
criminate between real and pseudoprogression after standard treatments, would be of great rel-
evance for evaluating MT1-MMP-specific antibodies as non-invasive diagnostic tools in clinic.
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In conclusion, we established the feasibility of the use of MT1-MMP-based immunoPET for
an efficient detection of GBM and it opens the possibility of using engineered anti-MT1-MMP
mAbs to more accurate biological characterization and diagnosis of GBM, as an alternate to
non-specific tracers.
Supporting Information
S1 Fig. MT1-MMP expression in GBM patients. A)MT1-MMP mRNA expression in the
REMBRANDT dataset stratified by histology: Non-tumor (n = 28), Oligodendroglioma
(n = 67), Astrocytoma (n = 147) and GBM (n = 219). Right panel: results of a Tukey’s HSD
post hoc test showing the differences between mean levels for each comparison and the 95%
confidence interval. B) Same as in A) with the patients stratified by tumor grade: Grade II
(n = 98), Grade III (n = 85), Grade IV (n = 130). C) Kaplan Meier survival estimates of GBM
patients in the REMBRANDT dataset stratified by the median MT1-MMP mRNA expres-
sion.
(TIF)
S2 Fig. (A) Hematoxylin and eosin (Left), immunohistochemistry with LEM2/15 antibody
(Center) and ex vivo autoradiography (Right) of the U251 s.c. xenograft from mouse injected
with 89Zr-DFO-LEM2/15, indicating there was specific uptake in the U251 tumor. (B) Hema-
toxylin and eosin (Left), immunohistochemistry with LEM2/15 antibody (Center), and ex
vivo autoradiography (Right) of the brain from a mouse with a TS543 orthotopic xenograft
injected with 89Zr-DFO-LEM2/15, confirming colocalization of the tracer with MT1-MMP
expression.
(TIF)
S3 Fig. (A) Uptake of 89Zr-DFO-LEM2/15 and 89Zr-DFO-IgG1 as isotype control in orthoto-
pic TS543 and U251 xenograft models, represented as %ID/g tumor (left panel) and tumor-
to-blood ratio (right panel) at days 2 and 4 p.i. Data of tumor-to-blood ratios from TS543
tumors are also shown in Fig 4, they are included here just for comparison. Horizontal bars
indicate medians. Red and blue lines represent ±SDs in TS543 and U251 xenografts, respec-
tively, (n = 3–5). (B) Analysis of BBB integrity by quantification of intravenously administered
Evans blue in the brain of mice with intact (●), mock surgery brains (&), orthotopic U251
(▲) and TS543 (▼) xenograft models. Horizontal bars indicate medians and vertical bars,
±SDs (n = 3).
(TIF)
S1 Video. PET-CT 3D render of a representative mouse bearing MT1-MMP+ GBM cells
(U251), right flank, and MT1-MMP- breast cancer cells (MCF-7), left flank, labeled with
89Zr-DFO-LEM 2/15 at 24 h post injection.
(MPG)
S2 Video. PET/CT 3D render imaging of a representative mouse bearing orthotopic xeno-
graft containing patient-derived TS543 neurospheres and labeled with 89Zr-DFO-LEM 2/
15 at 24h after injection
(MPG)
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